The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.
|Articles|July 9, 2015
- Gastrointestinal Cancers (Issue 5)
- Volume 4
- Issue 2
Survival Differences in KRAS/BRAF Mutations in mCRC
Author(s)Halfdan Sorbye, MD
Halfdan Sorbye, MD, professor, Department of Oncology and Medical Physics, Haukeland University Hospital, University of Bergen, discusses the survival differences in KRAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC).
Advertisement
Articles in this issue
over 11 years ago
Prevention and Screening of CRCover 11 years ago
Surivival Benefit of Regorafenib in CORRECT and CONCUR Trialsover 11 years ago
New Agents Show Potency for Patients with HCCover 11 years ago
Success of Regorafenib Confirmed in Patients With mCRCover 11 years ago
Agents Under Examination Demonstrate Success in Gastric CancerAdvertisement
Related to this article
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.
The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.
The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end point but reduced neurotoxicity.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5